The effects of the cholecystokinin (CCK)-receptor antagonist proglumide, the protease inhibitor gabexate, and the hormones secretin and cholecystokinin-octapeptide (CCK-8) were studied in a model of acute hemorrhagic pancreatitis induced by feeding mice a choline-deficient, ethionine-supplemented (CDE) diet.
Introduction
Severe acute hemorrhagic or necrotizing pancreatitis continues to result in significant morbidity and mortality. No specific therapy beyond supportive care has been proven to be clinically effective. The recent development of noninvasive, reproducible models of acute pancreatitis now enables us to study a variety of potentially beneficial agents.
We have previously shown that the cholecystokinin (CCK)'-receptor antagonist proglumide had protective effects against Receivedfor publication 4 February 1986.
1. Abbreviations used in this paper: CCK, cholecystokinin; CCK-8, cholecystokinin-octapeptide; CDE, choline-deficient, ethionine-supplemented; E, eosin; H, hematoxylin; s.c., subcutaneous.
caerulein-induced acute pancreatitis in mice, whereas secretin had only minor effects in this model (1) . Secretin had previously been proposed to have major beneficial effects on caeruleininduced pancreatitis in rats (2) and in dogs (3) . The recently developed serine protease inhibitor gabexate mesilate also had protective effects against acute experimental pancreatitis in rats (4) .
This study was performed to further evaluate the effects of gabexate, proglumide, and secretin in a model of acute hemorrhagic pancreatitis induced by feeding a choline-deficient, ethionine-supplemented (CDE) diet to young female mice (5) . The study was designed to investigate not only protective (prophylactic) effects, but also potentially therapeutic effects ofthese agents, once pancreatitis had already developed.
Methods
Materials. Gabexate mesilate was a generous gift from Sanol-Schwarz (Monheim, Federal Republic of Germany). Proglumide was a generous gift from Rotta Laboratorium (Milan, Italy) and Barrows Research Group, Inc. (Valley Stream, NY). Secretin (Kabi, Studsvik, Sweden) was purchased from Pharmacia Fine Chemicals (Piscataway, NJ), and cholecytokinin-octapeptide (CCK-8) was purchased from Squibb (Princeton, NJ).
Experimental protocol
Female Swiss Webster mice (Simonsen Laboratories, Gilroy, CA), [4] [5] [6] wk old and weighing 10-14 g, were used in this study. All mice were fed regular laboratory chow ad libitum before the experiments. The ethioninesupplemented (0.5% ethionine), choline-deficient (CDE) diet (test diet, Teklad, Madison, WI) was then substituted for a period of 66 h, after which it was replaced by regular chow. Mice were randomly assigned to the different treatment groups. For all conditions studied, unless otherwise indicated, blood samples and pancreatic tissue were collected from mice that had been fed the CDE diet for 54 h (six mice per set of determinations). These mice were not included in the survival analysis.
The first set of experiments examined whether any of the agents being studied were protective if given before the onset of pancreatitis (prophylactic regimen 
Biochemical determinations
Blood samples were collected from mixed arteriovenous blood after decapitation ofthe animals. Serum amylase concentration was determined after centrifugation of blood samples at 10,000 g for 10 min using the Phadebas amylase test (Pharmacia Fine Chemicals).
For determination of activated trypsin in pancreatic tissue, the pancreas was quickly removed and 75 mg of it was suspended in 2.5 ml of ice-cold 5 mM MgCl2 solution containing 0.1% Triton X-I00, and homogenized using an electrically driven teflon-glass pestle. All debris and nuclei were removed by centrifugation at 4VC for 20 min at 3,000 g and the supernatant was centrifuged at 1 00,000 g for 1 h (6). The supernatant was assayed for free tryptic activity by a fluorometric assay using N-carbobenzoxy-glycyl-glycyl-L-arginine-2-naphthylamide hydrochloride (GANA; Bachem, Inc., Torrance, CA) as substrate (7) . The protein concentration in the supernatant was determined using the Lowry method with bovine serum albumin as a standard (8) .
Measurement ofplasma CCK
Collection ofplasma. Mice were allowed free access to food during the entire study period, except for one group of chow-fed animals which were fasted overnight. Animals were killed by decapitation, and trunk blood was collected into iced heparinized tubes. The amount of blood obtained from each mouse ranged from 0.2 to 0.3 ml; therefore, blood samples from 6 to 8 mice from the same treatment group were pooled for each CCK determination. Blood was centrifuged at 4°C for recovery of plasma.
Assay ofplasma CCK Plasma CCK was measured by bioassay as previously described for rat and human plasma (9, 10 
Statistical analysis
Survival data of the different treatment groups were compared with survival in the control group of saline-injected, CDE-fed mice using a twotailed chi-square test. A two-tailed I test for independent samples was used to compare plasma CCK concentrations, serum amylase concentrations, and the amount ofactivated trypsin in the pancreas. Significance was assumed for P < 0.05.
Results
Effects of the CDE diet. Only 37% of mice that were fed the CDE diet and received saline injections survived ( . (Tables I and II) . However, at 54 h there was clear evidence of acute pancreatitis with significant increases in serum amylase concentration and activated trypsin in pancreatic tissue (Table I ) and histological evidence of acinar cell necrosis, intracellular vacuolization, and inflammation (Table II) . Thus, by 33 h on the CDE diet, acute pancreatitis had already been induced.
Effects of gabexate mesilate on CDE diet-induced pancreatitis. Prophylactic administration of this proteolytic enzyme inhibitor (i.e., starting the gabexate injection at the beginning of the CDE diet before the onset of pancreatitis) significantly improved survival from 37% in the control group to 85% (Table  I, Fig. 1 ). Both the increases in serum amylase concentration and pancreatic activated trypsin were also markedly reduced by prophylactic treatment with gabexate (Table I ). The histological features of necrosis and inflammation were essentially absent when gabexate treatment was started before the onset of pancreatitis, whereas the amount of intracellular vacuolization was only slightly reduced (Table II, Fig. 3) .
In marked contrast, survival was decreased to control values when gabexate treatment was started only after a severe pancreatitis had already been induced by 33 h of feeding the CDE Fig. 4 ). The increase in serum amylase concentration was virtually identical to the control value from mice that received saline injections, although the amount of pancreatic activated trypsin was significantly reduced in mice that received the therapeutic regimen of gabexate injections, as compared to the saline control (Table I ). The therapeutic gabexate treatment had no effect on any of the histopathological alterations (Table II) . CCK-8 given in addition to the prophylactic gabexate injections completely abolished the beneficial effect on survival seen with the prophylactic treatment and resulted in a 35% survival rate, which is virtually identical to the control value of 37% in the saline-injected mice (Table I, Fig. 4 ). The increase in serum amylase concentration was also not significantly different from control, whereas the amount of activated pancreatic trypsin was still slightly decreased in the mice that received CCK- the saline control (Table I) . CCK-8 completely abolished the beneficial effect of the prophylactic gabexate treatment seen on histological examination; all histopathological features graded were indistinguishable from the saline control (Table II) .
Effects ofproglumide on CDE diet-inducedpancreatitis. The prophylactic treatment with proglumide had marked beneficial effects on survival and on the biochemical and morphological features of acute pancreatitis, as did gabexate. Survival was significantly improved from 37% in the saline control to 75% with the prophylactic proglumide treatment (Table I , Fig. 1 ). Correspondingly, both the increases in serum amylase concentration' and in pancreatic activated trypsin were markedly reduced. Necrosis and inflammation were essentially absent with the prophylactic proglumide treatment, whereas there was still a substantial amount of intracellular vacuolization (histologically similar to those mice that received the prophylactic gabexate treatment) (Table II, Fig. 5 ).
In contrast to the gabexate experiments, proglumide still resulted in a significant improvement in survival when given after the induction of pancreatitis (i.e., as the therapeutic regimen of injections that were started after 33 h of feeding the CDE diet) (Table I, Fig. 6 ). Both the increases in serum amylase and in pancreatic activated trypsin were also significantly reduced by the therapeutic proglumide treatment compared with the saline control, although to a somewhat lesser degree than seen with the prophylactic proglumide treatment (Table I ). The histopathological alterations were also improved by the therapeutic proglumide treatment (Table II) . However, in contrast to the results seen with the prophylactic treatment, some necrosis of acinar cells and some inflammation were.present in the animals that received the therapeutic proglumide treatment (Table II) .
Injections ofCCK-8 in addition to the prophylactic treatment with the CCK-receptor antagonist proglumide completely abolished the beneficial effects on pancreatitis seen with the prophylactic proglumide treatment. Survival in the mice receiving CCK-8 in addition to proglumide (33%) was not significantly different from the 37% control value in the saline-injected mice (Table  I, Fig. 6 ). Both biochemical markers, serum amylase concentration and pancreatic activated trypsin, as well as all histopathological gradings were also indistinguishable from the control data in the saline-injected mice (Tables I and II, Fig. 7 For survival data see also Table II. prophylactic regimen of secretin injections had no significant effect on survival compared with the saline control (Table I, Fig. 2). Correspondingly, the increases in serum amylase concentration and in pancreatic activated trypsin were also unaffected by secretin (Table I) , although secretin appeared to slightly reduce the amount ofnecrosis, and to an even lesser degree, the amount of inflammation and intracellular vacuolization (Table II , Fig. 8 ).
Effects ofcholecystokinin on CDE diet-induced pancreatitis. Subcutaneous injections of 2 ,ug/kg CCK-8 at 6-h intervals throughout the 66-h period of feeding the CDE diet (i.e., 12 CCK injections) worsened the acute pancreatitis induced by the CDE diet alone. The increase in serum amylase concentration and in pancreatic activated trypsin were significantly greater than those caused by the diet alone (Table I) ; histological examination showed large areas of acinar cell necrosis and marked inflammation, as well as areas of fat necrosis and hemorrhage (Fig. 9) . The gradings ofthese histological alterations were the most severe in any of the groups studied (Table II) . Addition of CCK-8 also resulted in the worst outcome (21% survival). The difference compared with the 37% survival caused by the diet alone, however, did not reach statistical significance (Table I) . When chowfed mice were given 12 subcutaneous injections of 2 pg/kg CCK-8 at 6-h intervals, no adverse effects were observed (Tables I  and II) .
Plasma CCK concentrations. To determine whether the beneficial effects of the CCK-antagonist proglumide were related to the presence of elevated plasma CCK concentrations in mice on the CDE diet, plasma CCK concentrations were measured in mice on regular laboratory chow and in mice on the CDE diet. Chow-fed mice had fasting plasma CCK concentrations of 1.0±0.3 pM (mean±SD, n = 6) and of 7.9±1.2 (n = 5) while feeding ad libitum. Mice eating the CDE diet ad libitum had plasma concentrations of 1.2±0.2 pM (n = 3) after 15 h on the diet, 3 .1±2.1 (n = 4) after 30 h, and 1.7±0.7 (n = 7) after 60 h. All values were significantly lower (P < 0.005, two-tailed t test) than the plasma concentration in chow-fed animals eating ad libitum. Plasma CCK concentrations in mice receiving subcutaneous injections of proglumide (400 mg/kg) every 6 h for 60 h, whether receiving the chow or CDE diets ad libitum, were not significantly different from those measured in saline-injected controls on the same diets (5.5±0.6 [n = 4] for chow-fed mice and 1.8±0. 4 [n = 5] for CDE-diet-fed mice; P > 0.1).
Because CCK levels were low in animals on the CDE diet, it was important to determine if there was an inhibitor of CCK bioactivity in plasma that could interfere with the bioassay. To investigate this possibility, two experiments were performed. First, exogenous CCK-8 was added to plasma collected from normal mice and mice fed the CDE diet for 54 h. Plasma was then extracted and assayed for CCK bioactivity. The 54-h recoveries of exogenous CCK were 93±10% (mean±SD, n = 7) from normal mice and 73±2% (n = 4) from CDE-fed mice. Since this small difference in recoveries of CCK would not account for the marked suppression of CCK levels found in CDEtreated mice, a second study was done to determine if the recovery of CCK injected into CDE-fed mice was lower than that of normal animals. Normal mice and mice on the CDE diet for 30 h (n = 25 in each group) were injected subcutaneously with Figure 6 . Cumulative survival. Proglumide A represents experiments in which proglumide was given from the start of the CDE diet (prophylactic regimen), whereas proglumide B represents experiments in which proglumide was given only after the rats had been fed the CDE diet for 33 h (therapeutic regimen). Both the prophylactic and therapeutic proglumide treatments significantly improved survival compared to the saline-injected control (P < 0.01 by chi-square test). Injections of CCK-8 in addition to the prophylactic proglumide treatment (proglumide A + CCK-8), however, completely abolished the beneficial effect on survival (P > 0.30 compared with the saline-injected control group). For survival data see also Table II. 2 gg/kg CCK-8. Animals were sacrificed 30 min after injection and blood was collected for CCK assay. Plasma CCK levels in normal mice injected with CCK averaged 17.3±4.4 pM (mean+SD, n = 9) whereas those of CDE-treated mice were 32±5.3 pM (n = 6).
Discussion
The protease inhibitor gabexate had dramatic beneficial effects on survival and biochemical and histological alterations in this model of acute hemorrhagic pancreatitis when given before the onset of pancreatitis. The beneficial effects were essentially lost when gabexate was given later after initiation of acute pancreatitis, although the protease inhibitor still significantly decreased the amount of activated pancreatic trypsin. These observations cast some doubt on the potential for use ofthis protease inhibitor in human disease, where one is usually confronted with acute pancreatitis already far enough advanced to cause significant symptoms. The earlier protease inhibitor aprotinin (Trasylol) had been shown to be ineffective in the CDE diet model used in the present study, even as a prophylactic treatment (11) and in human acute pancreatitis (12, 13) . The dramatic beneficial effect seen with the prophylactic gabexate treatment in the present study contrasts with the ineffectiveness seen with aprotinin. This likely reflects the theoretical advantages that recently developed serine protease inhibitors have, compared with aprotinin. Gabexate is more potent and inhibits a greater number of proteolytic enzymes than does aprotinin (14, 15). With the development of even more potent protease inhibitors, such as camostate (FOY 305), which has a chemical structure similar to gabexate (14, 16, 17), a beneficial (or therapeutic) effect may be achieved even when the protease inhibitor is given later during the time course of acute pancreatitis. Thus, the present results suggest the need for further studies of the inhibition of tryptic activity and that of other serine proteases as a therapeutic factor in acute pancreatitis.
Secretin had been proposed to be protective against caeruleininduced acute pancreatitis in rats and dogs (2, 3) . Subsequent studies in the caerulein model in mice (1, 18) and in a model employing injections ofbile salts into the pancreatic duct ofrats (19, 20) did not show any major beneficial effect of secretin. The present results show that secretin had only very limited beneficial effects on the histological alterations and did not significantly ameliorate mortality or the biochemical alterations. The dose of secretin used in the present study was chosen from previous data, which showed that this dose of secretin had a small beneficial effect on caerulein-induced acute pancreatitis in mice (1) . Thus, both the present results and our previous study (1) indicate that secretin may have some small beneficial effect when given as a prophylactic treatment, but its therapeutic role in acute pancreatitis appears to be rather limited.
We have previously shown that the CCK-receptor antagonist proglumide had marked protective effects against caerulein-in- duced acute pancreatitis in mice (1 Plasma CCK concentrations were significantly decreased in the CDE-fed mice as compared with chow-fed controls. This was unexpected because a previous study had reported that secretion of digestive enzymes is decreased from pancreatic acini isolated from mice fed a CDE diet (21) . Thus, decreased intraluminal trypsin in the small intestine might be expected to lead to an increase in plasma CCK by loss of a feedback inhibitory mechanism as has been described in the rat (22) . The reasons for the unexpectedly low CCK concentrations in CDE-fed mice are unknown; it might be attributable to decreased food intake, a delay in gastric emptying, or altered amino acid composition of the food (CDE diet vs. chow). Also, the metabolism of circulating CCK might be considerably altered due to the severe disease state caused by the CDE diet.
Further control experiments were done to clarify if proglumide exerted its beneficial effects by a blockade of CCK receptors rather than some unknown, nonspecific mechanism unrelated to CCK. In these studies we sought to overcome the In addition, CCK injections also reduced the beneficial effect seen with the prophylactic gabexate treatment. Furthermore, CCK-8 worsened the severity of acute pancreatitis caused by the CDE diet alone (at least in terms of the biochemical and histological alterations, whereas the reduction in survival did not reach statistical significance). These observations further support the suggestion that CCK may play an important permissive or contributory role in the development of acute pancreatitis. In a previous study, caerulein had been shown to worsen the severity and mortality in a rat model of acute pancreatitis employing intraductal injections of bile salts (20). The mechanisms by which CCK contributes to the development of acute pancreatitis and by which blockade ofCCK receptors ameliorates acute pancreatitis are unknown. However, it appears unlikely that the beneficial effect of CCK-receptor blockade is merely due to a decrease in the amount of enzyme that is secreted into the acinar and ductal lumen, because other substances that can decrease enzyme secretion (such as atropine and glucagon) have failed to show beneficial effects in acute pancreatitis (15, 23, 24 ).
It appears more likely that inhibition of intracellular events related to stimulus-secretion coupling are responsible for the effect of CCK-receptor antagonists.
The dose of proglumide shown to have beneficial effects in this and a previous study is rather high (400 mg/kg every 6 h in the present study or 400 mg/kg per h in the previous study [1] ). This would require doses of 28 g proglumide per injection for a 70-kg patient, which cannot be administered in clinical practice. However, proglumide analogues and a nonpeptide CCK receptor antagonist isolated from Aspergillus alliaceus have recently been developed that are 75-1,000 times more potent than proglumide (25) (26) (27) . Thus, the dose of a more potent proglumide analogue required for effective CCK receptor blockade in a human, potentially having a beneficial effect on acute pancreatitis, may be comparable to doses of cimetidine or ranitidine required to inhibit gastric acid secretion and accelerate duodenal ulcer healing.
